MUC16 as a novel target for cancer therapy

Abhijit Aithal, Sanchita Rauth, Prakash Kshirsagar, Ashu Shah, Imayavaramban Lakshmanan, Wade M. Junker, Maneesh Jain, Moorthy Palanimuthu Ponnusamy, Surinder Kumar Batra

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: MUC16 is overexpressed in multiple cancers and plays an important role in tumorigenicity and acquired resistance to therapy. Area covered: In this review, we describe the role of MUC16 under normal physiological conditions and during tumorigenesis. First, we provide a summary of research on MUC16 from its discovery as CA125 to present anti-MUC16 therapy trials that are currently in the initial phases of clinical testing. Finally, we discuss the reasons for the limited effectiveness of these therapies and discuss the direction and focus of future research. Expert opinion: Apart from its protective role in normal physiology, MUC16 contributes to disease progression and metastasis in several malignancies. Due to its aberrant overexpression, it is a promising target for diagnosis and therapy. Cleavage and shedding of its extracellular domain is the major barrier for efficient targeting of MUC16-expressing cancers. Concerted efforts should be undertaken to target the noncleaved cell surface retained portion of MUC16. Such efforts should be accompanied by basic research to understand MUC16 cleavage and decipher the functioning of MUC16 cytoplasmic tail. While previous efforts to activate anti-MUC16 immune response using anti-CA125 idiotype antibodies have met with limited success, ideification of neo-antigenic epitopes in MUC16 that correlate with improved survival have raised raised hopes for developing MUC16-targeted immunotherapy.

Original languageEnglish (US)
Pages (from-to)675-686
Number of pages12
JournalExpert Opinion on Therapeutic Targets
Volume22
Issue number8
DOIs
StatePublished - Aug 3 2018

Fingerprint

Physiology
Epitopes
Neoplasms
Antibodies
Expert Testimony
Testing
Therapeutics
Research
Immunotherapy
Disease Progression
Anti-Idiotypic Antibodies
Carcinogenesis
Neoplasm Metastasis
Direction compound

Keywords

  • MUC16
  • cancer therapy
  • immunotherapy
  • mucins
  • targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Aithal, A., Rauth, S., Kshirsagar, P., Shah, A., Lakshmanan, I., Junker, W. M., ... Batra, S. K. (2018). MUC16 as a novel target for cancer therapy. Expert Opinion on Therapeutic Targets, 22(8), 675-686. https://doi.org/10.1080/14728222.2018.1498845

MUC16 as a novel target for cancer therapy. / Aithal, Abhijit; Rauth, Sanchita; Kshirsagar, Prakash; Shah, Ashu; Lakshmanan, Imayavaramban; Junker, Wade M.; Jain, Maneesh; Palanimuthu Ponnusamy, Moorthy; Batra, Surinder Kumar.

In: Expert Opinion on Therapeutic Targets, Vol. 22, No. 8, 03.08.2018, p. 675-686.

Research output: Contribution to journalReview article

Aithal A, Rauth S, Kshirsagar P, Shah A, Lakshmanan I, Junker WM et al. MUC16 as a novel target for cancer therapy. Expert Opinion on Therapeutic Targets. 2018 Aug 3;22(8):675-686. https://doi.org/10.1080/14728222.2018.1498845
Aithal, Abhijit ; Rauth, Sanchita ; Kshirsagar, Prakash ; Shah, Ashu ; Lakshmanan, Imayavaramban ; Junker, Wade M. ; Jain, Maneesh ; Palanimuthu Ponnusamy, Moorthy ; Batra, Surinder Kumar. / MUC16 as a novel target for cancer therapy. In: Expert Opinion on Therapeutic Targets. 2018 ; Vol. 22, No. 8. pp. 675-686.
@article{4e855dc219864d95ac5baeb711dc05d5,
title = "MUC16 as a novel target for cancer therapy",
abstract = "Introduction: MUC16 is overexpressed in multiple cancers and plays an important role in tumorigenicity and acquired resistance to therapy. Area covered: In this review, we describe the role of MUC16 under normal physiological conditions and during tumorigenesis. First, we provide a summary of research on MUC16 from its discovery as CA125 to present anti-MUC16 therapy trials that are currently in the initial phases of clinical testing. Finally, we discuss the reasons for the limited effectiveness of these therapies and discuss the direction and focus of future research. Expert opinion: Apart from its protective role in normal physiology, MUC16 contributes to disease progression and metastasis in several malignancies. Due to its aberrant overexpression, it is a promising target for diagnosis and therapy. Cleavage and shedding of its extracellular domain is the major barrier for efficient targeting of MUC16-expressing cancers. Concerted efforts should be undertaken to target the noncleaved cell surface retained portion of MUC16. Such efforts should be accompanied by basic research to understand MUC16 cleavage and decipher the functioning of MUC16 cytoplasmic tail. While previous efforts to activate anti-MUC16 immune response using anti-CA125 idiotype antibodies have met with limited success, ideification of neo-antigenic epitopes in MUC16 that correlate with improved survival have raised raised hopes for developing MUC16-targeted immunotherapy.",
keywords = "MUC16, cancer therapy, immunotherapy, mucins, targeted therapy",
author = "Abhijit Aithal and Sanchita Rauth and Prakash Kshirsagar and Ashu Shah and Imayavaramban Lakshmanan and Junker, {Wade M.} and Maneesh Jain and {Palanimuthu Ponnusamy}, Moorthy and Batra, {Surinder Kumar}",
year = "2018",
month = "8",
day = "3",
doi = "10.1080/14728222.2018.1498845",
language = "English (US)",
volume = "22",
pages = "675--686",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - MUC16 as a novel target for cancer therapy

AU - Aithal, Abhijit

AU - Rauth, Sanchita

AU - Kshirsagar, Prakash

AU - Shah, Ashu

AU - Lakshmanan, Imayavaramban

AU - Junker, Wade M.

AU - Jain, Maneesh

AU - Palanimuthu Ponnusamy, Moorthy

AU - Batra, Surinder Kumar

PY - 2018/8/3

Y1 - 2018/8/3

N2 - Introduction: MUC16 is overexpressed in multiple cancers and plays an important role in tumorigenicity and acquired resistance to therapy. Area covered: In this review, we describe the role of MUC16 under normal physiological conditions and during tumorigenesis. First, we provide a summary of research on MUC16 from its discovery as CA125 to present anti-MUC16 therapy trials that are currently in the initial phases of clinical testing. Finally, we discuss the reasons for the limited effectiveness of these therapies and discuss the direction and focus of future research. Expert opinion: Apart from its protective role in normal physiology, MUC16 contributes to disease progression and metastasis in several malignancies. Due to its aberrant overexpression, it is a promising target for diagnosis and therapy. Cleavage and shedding of its extracellular domain is the major barrier for efficient targeting of MUC16-expressing cancers. Concerted efforts should be undertaken to target the noncleaved cell surface retained portion of MUC16. Such efforts should be accompanied by basic research to understand MUC16 cleavage and decipher the functioning of MUC16 cytoplasmic tail. While previous efforts to activate anti-MUC16 immune response using anti-CA125 idiotype antibodies have met with limited success, ideification of neo-antigenic epitopes in MUC16 that correlate with improved survival have raised raised hopes for developing MUC16-targeted immunotherapy.

AB - Introduction: MUC16 is overexpressed in multiple cancers and plays an important role in tumorigenicity and acquired resistance to therapy. Area covered: In this review, we describe the role of MUC16 under normal physiological conditions and during tumorigenesis. First, we provide a summary of research on MUC16 from its discovery as CA125 to present anti-MUC16 therapy trials that are currently in the initial phases of clinical testing. Finally, we discuss the reasons for the limited effectiveness of these therapies and discuss the direction and focus of future research. Expert opinion: Apart from its protective role in normal physiology, MUC16 contributes to disease progression and metastasis in several malignancies. Due to its aberrant overexpression, it is a promising target for diagnosis and therapy. Cleavage and shedding of its extracellular domain is the major barrier for efficient targeting of MUC16-expressing cancers. Concerted efforts should be undertaken to target the noncleaved cell surface retained portion of MUC16. Such efforts should be accompanied by basic research to understand MUC16 cleavage and decipher the functioning of MUC16 cytoplasmic tail. While previous efforts to activate anti-MUC16 immune response using anti-CA125 idiotype antibodies have met with limited success, ideification of neo-antigenic epitopes in MUC16 that correlate with improved survival have raised raised hopes for developing MUC16-targeted immunotherapy.

KW - MUC16

KW - cancer therapy

KW - immunotherapy

KW - mucins

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85051518401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051518401&partnerID=8YFLogxK

U2 - 10.1080/14728222.2018.1498845

DO - 10.1080/14728222.2018.1498845

M3 - Review article

C2 - 29999426

AN - SCOPUS:85051518401

VL - 22

SP - 675

EP - 686

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 8

ER -